XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 87.13

Change

0.00 (0.00)%

Market Cap

N/A

Volume

6.39M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-15 )

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

N/A

USD 0.07B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.25% 19% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.25% 19% F 35% F
Trailing 12 Months  
Capital Gain -8.00% 19% F 23% F
Dividend Return 0.14% 19% F 1% F
Total Return -7.87% 19% F 20% F
Trailing 5 Years  
Capital Gain 32.12% 24% F 42% F
Dividend Return 0.71% 26% F 2% F
Total Return 32.83% 24% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -4.21% 14% F 15% F
Dividend Return -4.14% 14% F 10% F
Total Return 0.07% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 28.75% 19% F 37% F
Risk Adjusted Return -14.39% 14% F 13% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.